This week's sponsor is FierceBiotech’s Drug Development Forum. | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration. Register now | Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. | |
| Top Stories Of The Week Thursday, June 30, 2016 Boehringer Ingelheim’s U.S. unit has joined the pharmas cutting back their sales operations to squeeze costs. The Germany-based company plans to delete 724 jobs from its payroll, mostly in sales, according to a notice filed Wednesday with the state of Connecticut. Read more from FiercePharma Tuesday, July 5, 2016 A trio of collaborators announced Monday clinical trial data showing that an implantable neuromodulation device improved symptoms of rheumatoid arthritis. The results may also have an impact on patients with other inflammatory diseases, such as Parkinson’s, Alzheimer’s and Crohn’s disease. Read more from FierceMedicalDevices Wednesday, July 6, 2016 Pfizer and the city of Chicago have hammered out an agreement on painkiller marketing, setting out a code of conduct to help ensure the powerful drugs are prescribed to the right patients and used with all their serious risks in mind. Read more from FiercePharmaMarketing Monday, July 4, 2016 Roche is set to lay off 350 IT employees in the U.S., Switzerland and other European countries, Basler Zeitung reports. The move amounts to a reallocation of resources from expensive locations including San Francisco to Roche’s shared service centers in Warsaw, Kuala Lumpur and other cities. Read more from FierceBiotechIT Tuesday, July 5, 2016 Aurobindo Pharma wants to snap up some of the generics up for grabs from Teva Pharmaceutical Industries as it sells products to meet antitrust concerns so it can buy the generics business of Allergan. Read more from FiercePharmaAsia Wednesday, June 29, 2016 The FDA has been closely scrutinizing Chinese production facilities, and now two Chinese companies with ties to Western drugmakers have been called on the mat to account for problems in their manufacturing. The FDA has issued warning letters to plants operated by Shanghai Desano Chemical Pharmaceutical and Chongqing Lummy Pharmaceutical, slamming them both for manipulating testing and turning in falsified batch test results on APIs. Read more from FiercePharmaManufacturing Wednesday, July 6, 2016 In Alzheimer’s disease, the interaction between the buildup of tau proteins inside brain nerve cells and the accumulation of beta-amyloid outside these cells has been unclear. Using mouse models, Johns Hopkins scientists have shed light on this relationship, which could pave the way to more effective therapies. Read more from FierceBiotechResearch Tuesday, July 5, 2016 Researchers already knew that the protection offered by GlaxoSmithKline’s malaria vaccine--the world’s first--wanes over time. But new data shows it may dwindle to nearly nothing sooner than they expected. Read more from FierceVaccines Tuesday, July 5, 2016 Questions about Merck CEO Kenneth Frazier's dedication to animal health have been raised in the past, but the company just made a big acquisition that shows it's still a major player in the industry. Read more from FierceAnimalHealth Wednesday, July 6, 2016 Germany’s Evotec has penned a new deal with a leading U.S. university that will see it gain access to one of the hottest tickets in drug development--CRISPR Cas9 gene editing technology. Read more from FierceCRO Events NOVEMBER 16-17, 2016 | BOSTON, MA | Presented By Speid Associates | |